Barclays analyst Etzer Darout reiterated an Overweight rating and $224.00 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ)The analyst commented, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE